Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Pacific Biosciences of California, Inc. PACB

Healthcare — Medical Devices
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
1.31
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — 3 3 1 — — — 1 —
Insider Ownership
8.21%

Capital & Financial Ratios

Market Cap
427.96
Revenue
159.27
Net Income
(131.39)
Free Cash Flow
(80.48)
Net Debt
407.43
Current Ratio
4.92
Debt/Equity
(19.40)
P/E ratio
0.00
P/S ratio
2.67
P/B ratio
0.00
Past 5Y EPS Growth
(23.55%)
This Y EPS Growth
74.73%
Next Y EPS Growth
1.17%
Next 5Y EPS Growth
41.93%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 631.72 390.62 279.53 236.91
Receivables 36.62 27.52 35.45 31.10
Inventory 56.68 58.76 49.29 61.08
Other — — — —
742.05 495.68 375.05 338.64
2023 2024 2025 Q'26
Payables 15.06 16.59 20.77 19.22
ST’ Debt — — — —
Other 8.33 3.22 2.03 1.79
95.03 66.30 72.83 68.81
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 37.18 39.01 — —
—
’25 37.15 39.77 38.44 44.65
160.01
’24 38.81 36.01 39.97 39.22
154.01
’23 38.90 47.57 55.69 58.36
200.52
’22 33.17 35.47 32.31 27.35
128.30
’21 29.00 30.61 34.89 36.02
130.51
’20 15.60 17.08 19.08 27.14
78.89
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (44.69) (35.58) — —
—
’25 (44.06) (29.38) (18.71) (19.07)
(111.21)
’24 (75.68) (54.26) (45.46) (30.65)
(206.06)
’23 (94.69) (41.74) (65.18) (57.56)
(259.17)
’22 (79.03) (60.56) (63.05) (60.57)
(263.21)
’21 (23.10) (15.71) (40.66) (31.71)
(111.18)
’20 75.36 (23.79) (17.81) (14.26)
19.50
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (2.73) (39.19) — —
—
’25 (50.44) (29.93) (18.62) (19.93)
(118.92)
’24 (79.56) (55.74) (44.68) (32.27)
(212.25)
’23 (98.41) (44.01) (66.01) (59.58)
(268.02)
’22 (82.67) (64.58) (67.24) (65.65)
(280.14)
’21 (23.50) (17.28) (41.77) (34.55)
(117.11)
’20 75.25 (24.11) (18.34) (14.33)
18.46
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.03) (0.14) — —
—
’25 (1.44) (0.14) (0.13) (0.13)
(1.82)
’24 (0.29) (0.64) (0.22) (0.49)
(1.58)
’23 (0.36) (0.28) (0.26) (0.31)
(1.21)
’22 (0.37) (0.32) (0.34) (0.37)
(1.40)
’21 (0.45) (0.21) 0.08 (0.31)
(0.89)
’20 0.01 (0.15) (0.14) 0.37
0.17

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 3.85 5.74 1.16 0.85 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.01 14.55 9.99 2.73 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 769 796 575 485 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.17 0.25 0.27 0.33 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 128.30 200.52 154.01 160.01 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 38.22% 26.32% 24.21% 28.61% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (314.25) (318.16) (309.53) (546.06) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (244.92%) (158.67%) (200.98%) (341.28%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (314.25) (306.73) (309.85) (546.38) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.07 13.69 224.81 397.05 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.57 0.79 0.56 0.53 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ (1.40) (1.21) (1.12) (1.82) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.17) (1.02) (0.75) (0.37) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.08) (0.03) (0.02) (0.03) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.25) (1.06) (0.77) (0.40) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.51 2.77 1.85 0.02 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 224.55 253.63 274.49 299.96 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.90 12.13 3.26 3.51 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.17 3.47 0.99 104.86 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.95 13.47 4.99 5.85 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.85) (10.08) (3.62) (7.87) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (263.21) (259.17) (206.06) (111.21) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.93) (8.84) (6.19) (7.71) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (280.14) (268.02) (212.25) (118.92) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 588.74 647.02 429.38 302.22 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 907.68 892.24 647.49 645.38 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 135.07 260.53 256.87 365.86 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 562.90 701.30 506.59 5.35 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.65%) (17.46%) (20.61%) (53.45%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (27.51%) (21.73%) (38.83%) (93.25%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (46.42%) (48.53%) (51.30%) (213.45%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Pacific Biosciences (PACB), a pioneer in long-read DNA sequencing, trades at a steep 75% discount to average analyst targets amid post-pandemic biotech funding woes and fierce competition, yet faces polarized views with potential 40% downside risk at the low end. The stock’s volatile history—peaking at $54 in 2021 on COVID-driven growth and the $2.3 billion Omniome acquisition, then cratering over 95%—reflects execution challenges in scaling Revio and Onso platforms against rivals like Oxford Nanopore. Recent stabilization follows multi-year declines, with revenue peaking at $200 million in 2023 before a 23% drop to $154 million in 2024, offset by efficiency gains like 6% higher revenue per employee amid headcount cuts.

Profitability remains elusive, with net losses swelling to -$310 million in 2024 and projected at -$553 million in 2025 before narrowing, driven by gross margin erosion to 24%, massive depreciation, and 208% share dilution. Cash burn persists at -$212 million FCF, with net debt at $257 million after deleveraging from acquisition highs, while ROE languishes at -51% versus peers. Insider sells without buys signal caution in this high-beta play.

Analysts forecast revenue recovery to $200 million by 2027 (15% CAGR tail), EPS improvement to -$0.49, and potential profitability inflection if margins rebound above 30% and AI-genomics tailwinds materialize in a $30 billion market. Yet risks loom from VC droughts, debt refinancing, China exposure, and competition—offering speculative upside for patient investors betting on biotech revival.

Read full commentary →

Pacific Biosciences of California, Inc. (PACB) Latest News

News by impact score

Fine-tune

20 Sep

4 www.marketbeat.com, 2:02 AM
Pacific Biosciences targets clinical growth and $40 million savings through HiFi sequencing push. HiFi sequencing initiative targets clinical expansion and major cost reductions.

8 Sep

3 , 12:23 PM
PacBio reported Q2 earnings, with results compared directly to peers in the life sciences tools and services sector to highlight relative performance. Q2 earnings data can shift near-term investor sentiment and valuations but rarely alters long-term company trajectory on its own.

2 Sep

4 , 1:55 PM
Pacific Biosciences of California cuts its 2026 outlook as clinical adoption of its products encounters a critical test. Outlook reduction points to major adoption barriers likely to slow revenue growth and shift investor views.

16 Aug

4 www.marketbeat.com, 3:01 AM
PacBio cuts outlook due to slower SPRQ-Nx transition and targets cash-flow positivity by 2028. Outlook reduction and delayed SPRQ-Nx transition point to major near-term setbacks that can shift company trajectory and investor sentiment.

14 Aug

3 , 5:17 AM
PacBio’s Q2 earnings call included five key analyst questions on company performance and outlook. Analyst questions from the earnings call can highlight operational issues or growth prospects affecting near-term sentiment.

6 Aug

4 , 1:04 PM
Pacific Biosciences reported Q2 earnings that met estimates but missed revenue targets. The company cut its 2026 sales outlook. Cut 2026 sales guidance signals weaker growth prospects and reduced investor confidence.

4 transcript www.marketbeat.com, 12:03 AM
Pacific Biosciences of California held its Q2 earnings call covering financial results, operational updates, and forward guidance for the sequencing technology firm. Earnings call details directly disclose quarterly results and strategy shifts that move investor sentiment and stock trajectory.

5 Aug

4 , 4:08 PM
Pacific Biosciences of California appoints Mark Van Oene as President and Chief Executive Officer. CEO appointment signals major leadership shift likely to influence strategy and investor sentiment.

4 , 4:05 PM
Pacific Biosciences of California reported financial results for the second quarter of 2026. Quarterly financial results directly affect valuation and investor sentiment.

4 , 9:05 AM
PacBio announced faster runs, up to 50% more HiFi data, and new compliance controls for the Vega system. Vega system upgrades deliver faster sequencing runs and 50% more HiFi data output plus compliance features that strengthen PacBio's core product performance and competitive position.

3 , 6:10 PM
Pacific Biosciences of California reported a Q2 loss and missed revenue estimates. Q2 loss and revenue shortfall may pressure near-term stock performance and investor views on operations.

3 , 5:27 PM
Pacific Biosciences of California reported Q2 CY2026 sales below analyst estimates. Missing sales estimates can pressure near-term stock performance and investor views on execution.

4 Aug

3 app.moby.co, 8:30 AM
Pacific Biosciences of California, Inc. Q2 2026 earnings call summary released. Q2 earnings data can shift market expectations for financial performance and outlook.

26 May

4 GlobeNewswire, 9:05 AM
PacBio SPRQ-Nx Chemistry begins worldwide shipping, enabling sub-$300 HiFi genomes for large-scale projects and AI-enhanced sequencing. Worldwide rollout of SPRQ-Nx chemistry directly cuts HiFi genome costs below $300 and supports AI sequencing, materially expanding commercial reach.

20 May

3 Zacks, 11:15 AM
Pacific Biosciences of California, Inc. (PACB) partners with Blank Bio to advance RNA foundation models in oncology. Partnership targets RNA model advancement in oncology and may support PACB product innovation without guaranteeing major trajectory shifts.

19 May

4 Business Wire, 9:00 AM
Blank Bio announced seed financing and a strategic collaboration with Pacific Biosciences of California to develop RNA foundation models for precision oncology. Strategic collaboration advances PacBio RNA technologies and strengthens its positioning in precision oncology markets.

13 May

4 Insider Monkey, 2:20 AM
Pacific Biosciences (PACB) reports Q1 EPS. Q1 EPS report delivers key financial results that significantly influence PACB's market performance and investor sentiment.

12 May

4 StockStory, 4:36 PM
PacBio (PACB) shares plunged more than 30% today after Q2 revenue of $37.1 million missed estimates of $42.3 million, EPS loss widened to $0.81 from expected $0.74, and Q3 guidance disappointed at $36-38 million. Earnings miss and weak guidance triggered massive sell-off, signaling challenges to near-term financial performance and investor sentiment.

3 StockStory, 12:20 PM
PACB Q1 results show consumables growth and rising clinical adoption offsetting weaker instrument sales. Consumables growth and clinical adoption balance instrument weakness, moderately influencing Q1 financial performance and market sentiment.

11 May

3 GlobeNewswire, 9:05 AM
HiFi Solves Sub-fertility Consortium in Asia Pacific reports first major study using Pacific Biosciences' HiFi long-read sequencing to investigate unexplained subfertility and recurrent pregnancy loss. First major study using HiFi sequencing in subfertility research validates PACB's technology in clinical genomics and expands market potential in Asia Pacific.

8 May

3 Zacks, 10:39 AM
Pacific Biosciences (PACB) Q1 earnings beat estimates, but revenues missed forecasts and gross margins declined. Mixed Q1 results with earnings beat offset by revenue miss and gross margin drop moderately influence financial performance and investor sentiment.

3 app.moby.co, 8:30 AM
Pacific Biosciences of California, Inc. (PACB) released Q1 2026 earnings call summary covering quarterly financial results, operational updates, and future guidance. Quarterly earnings summaries provide key insights into financial health and guidance, moderately influencing investor sentiment and stock performance.

3 www.marketbeat.com, 8:07 AM
Pacific Biosciences of California (PACB) released Q1 earnings call highlights covering financial results, operational updates, and future outlook. Q1 earnings call highlights impact financial performance and investor sentiment but are balanced by market factors.

7 May

4 GlobeNewswire, 4:05 PM
PacBio announced first quarter 2026 financial results. Quarterly earnings announcements significantly impact PACB's stock price and investor perceptions of future performance.

3 Zacks, 5:55 PM
Pacific Biosciences of California, Inc. (PACB) reported a Q1 net loss and revenue below analyst estimates. Q1 loss and revenue shortfall indicate weaker financial performance, likely causing moderate short-term pressure on stock price and investor sentiment.

3 StockStory, 4:22 PM
PacBio (NASDAQ:PACB) missed Q1 CY2026 sales expectations, reporting lower-than-anticipated revenue. Sales miss affects financial performance and investor sentiment but is limited to quarterly results.

21 Apr

3 , 9:05 AM
PacBio and Lucid Genomics announced a compatibility collaboration to advance tertiary analysis for long-read sequencing. Collaboration enhances ecosystem for PacBio's core long-read sequencing technology, aiding product innovation and competitive positioning.

17 Apr

4 Zacks, 10:09 AM
PacBio stock rose after announcing a new FFPE workflow that significantly boosts cancer sequencing performance, enabling higher-quality analysis from preserved tissue samples. New FFPE workflow strengthens PacBio's oncology sequencing capabilities, driving immediate stock gains and potential long-term market share expansion.

15 Apr

4 , 9:05 AM
PacBio and Covaris announce joint workflow enabling HiFi long-read sequencing of FFPE tumor samples. Joint workflow enables HiFi sequencing of challenging FFPE tumor samples, expanding PacBio's oncology applications and competitive edge.

14 Apr

4 Insider Monkey, 1:29 AM
Pacific Biosciences (PACB) draws investor attention for its involvement in the Trillion Gene Atlas Program, a massive initiative to sequence one trillion human genes using long-read technology. Involvement in the Trillion Gene Atlas Program boosts PACB's visibility, validates its long-read sequencing tech, and opens doors to major contracts and partnerships in genomics.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us